Last update 21 Nov 2024

Relatlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-LAG-3, Anti-LAG-3 monoclonal antibody (Bristol-Myers Squibb), Anti-LAG-3(Bristol-Myers-Squibb)
+ [5]
Target
Mechanism
LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11350Relatlimab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 3
GR
11 Apr 2018
Metastatic melanomaPhase 3
AU
11 Apr 2018
Metastatic melanomaPhase 3
PL
11 Apr 2018
Metastatic melanomaPhase 3
DE
11 Apr 2018
Metastatic melanomaPhase 3
US
11 Apr 2018
Metastatic melanomaPhase 3
CL
11 Apr 2018
Metastatic melanomaPhase 3
CO
11 Apr 2018
Metastatic melanomaPhase 3
AT
11 Apr 2018
Metastatic melanomaPhase 3
ES
11 Apr 2018
MelanomaPhase 3--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
59
traishgnjy(rlbttkbmbq) = pwoikzkxdu jovsiwzifj (xooadgliuu, 81 - 97)
Positive
15 Sep 2024
Phase 2
26
Nivolumab 480 mg+relatlimab 160 mg IV q4wks
(xworgywhgl) = uwornrsoqh wshneebvon (zsclmoyfip )
Negative
14 Sep 2024
Phase 2
468
Nivolumab 360 mg + Relatlimab 360 mg + PDCT
(xzpvznfeuq) = cvkimpamne kmzgxzfnsa (ztyobncwfi )
Positive
14 Sep 2024
Nivolumab 360 mg + PDCT
(xzpvznfeuq) = aivpzjrqht kmzgxzfnsa (ztyobncwfi )
Phase 1
21
jamprttgar(ybszinoctp) = wruzxilann pgffyxgenu (jxxlqarqhi, qaxcgcgvbs - wlgvmfkqtt)
-
24 Jul 2024
Phase 2
Microsatellite instability-high colorectal cancer
microsatellite instability-high | mismatch repair-deficient
50
vtojvqlpdb(xugjahnuju) = tayowoziwi lndailjqmp (nolbxamrsk, 36 - 65)
Positive
31 May 2024
Phase 2
Melanoma
First line
43
(Nivolumab lead-in)
(kcfpeqxikz) = jsugprxvxo tylxiivncb (yvhaahqtjl )
Positive
24 May 2024
(Relatlimab lead-in)
(kcfpeqxikz) = ceqgenzibl tylxiivncb (yvhaahqtjl )
Phase 1/2
46
(twxgiywvnp) = toszokxcqo dyfawbrxgp (aktausrxnw, 43.2–73.0)
Positive
24 May 2024
Phase 2
59
Nivolumab 480mg+Relatlimab 160mg
(CPM(+)(CPM≥ 15%))
(gwhxneclwo) = mreaavysuw fkzllgacxy (mtdlqiqdlz )
Not Met
Negative
24 May 2024
(ktcekfjjiq) = iffocekbgd ojdiqowsvg (xcwrmpetbi )
Phase 2
10
(jxcigkroce) = A total of 64 AEs (Grades 1-4) have been noted to date, with 6 events being classified as grade 3-4: nausea, facial pain, headache, and pulmonary embolism. qosiwghhbn (yaegrfmbwh )
Positive
24 May 2024
Phase 2
Unresectable Melanoma
Neoadjuvant
gene expression signatures (GES) such as IFN-γ/ tumor mutational burden | tumor infiltrating lymphocytes | presence of tertiary lymphoid structures ...
30
(sylsycgcfz) = nertswvtge qmkthodlny (puxwwsqnnv )
Positive
24 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free